Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TropicALL: Thromboprophylaxis in Children with Acute Lymphoblastic Leukemia Using Low-molecular-weight Heparin
2014-003303-30Phase 3Terminated
- Sponsor
- Dutch Childhood Oncology Group
- Start
- Nov 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of nadroparin in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Dutch Childhood Oncology Group. Primary endpoint: Incidence of symptomatic objectified venous thromboembolism (VTE). Started Nov 2014; status: terminated.
02
Drugs
nadroparin
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2014-003303-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003303-30.